Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Orphan Drugs May Grow More Common As Medicine Becomes More Personal

Executive Summary

As drug research increasingly focuses on identifying patients who will most benefit from a given therapy, more drugs will qualify for orphan status and companies will be able to take advantage of the economic incentives to develop those drugs

You may also be interested in...

With Promise Of Post-Market Safety Studies, Panel Backs Amgen’s Nplate

FDA's new authority to require post-market studies under the FDA Amendments Act could be the ticket to approval for Amgen's platelet producer Nplate (romiplostim)

Orphan Drugs Would Get User Fee Waivers With Greater Ease Under House Bill

Provisions in the House version of the FDA user fee bill would raise the cut-off for an orphan drug to qualify for a user fee waiver from firms with less than $10 million in annual revenue to firms with less then $100 million

Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says

Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts